Search tips
Search criteria 


Logo of jrsocmedLink to Publisher's site
J R Soc Med. 1996; 89(Suppl 27): 8–13.
PMCID: PMC1295619

Role of corticosteroids in cystic fibrosis lung disease.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.0M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med. 1995 Mar 30;332(13):848–854. [PubMed]
  • Auerbach HS, Williams M, Kirkpatrick JA, Colten HR. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet. 1985 Sep 28;2(8457):686–688. [PubMed]
  • Eigen H, Rosenstein BJ, FitzSimmons S, Schidlow DV. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group. J Pediatr. 1995 Apr;126(4):515–523. [PubMed]
  • Hiller EJ. Pathogenesis and management of aspergillosis in cystic fibrosis. Arch Dis Child. 1990 Apr;65(4):397–398. [PMC free article] [PubMed]
  • Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med. 1995 Apr;151(4):1075–1082. [PubMed]
  • Dean TP, Dai Y, Shute JK, Church MK, Warner JO. Interleukin-8 concentrations are elevated in bronchoalveolar lavage, sputum, and sera of children with cystic fibrosis. Pediatr Res. 1993 Aug;34(2):159–161. [PubMed]
  • Fick RB, Jr, Robbins RA, Squier SU, Schoderbek WE, Russ WD. Complement activation in cystic fibrosis respiratory fluids: in vivo and in vitro generation of C5a and chemotactic activity. Pediatr Res. 1986 Dec;20(12):1258–1268. [PubMed]
  • Konstan MW, Walenga RW, Hilliard KA, Hilliard JB. Leukotriene B4 markedly elevated in the epithelial lining fluid of patients with cystic fibrosis. Am Rev Respir Dis. 1993 Oct;148(4 Pt 1):896–901. [PubMed]
  • Fujishima S, Aikawa N. Neutrophil-mediated tissue injury and its modulation. Intensive Care Med. 1995 Mar;21(3):277–285. [PubMed]
  • Birrer P, McElvaney NG, Rüdeberg A, Sommer CW, Liechti-Gallati S, Kraemer R, Hubbard R, Crystal RG. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med. 1994 Jul;150(1):207–213. [PubMed]
  • Vingerling JR, Dielemans I, Witteman JC, Hofman A, Grobbee DE, de Jong PT. Macular degeneration and early menopause: a case-control study. BMJ. 1995 Jun 17;310(6994):1570–1571. [PMC free article] [PubMed]
  • Konstan MW, Hilliard KA, Norvell TM, Berger M. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med. 1994 Aug;150(2):448–454. [PubMed]
  • Cantin A. Cystic fibrosis lung inflammation: early, sustained, and severe. Am J Respir Crit Care Med. 1995 Apr;151(4):939–941. [PubMed]
  • Balough K, McCubbin M, Weinberger M, Smits W, Ahrens R, Fick R. The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr Pulmonol. 1995 Aug;20(2):63–70. [PubMed]
  • Bonfield TL, Konstan MW, Burfeind P, Panuska JR, Hilliard JB, Berger M. Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis. Am J Respir Cell Mol Biol. 1995 Sep;13(3):257–261. [PubMed]
  • Munck A, Mendel DB, Smith LI, Orti E. Glucocorticoid receptors and actions. Am Rev Respir Dis. 1990 Feb;141(2 Pt 2):S2–10. [PubMed]
  • Robinson DS, Durham SR, Kay AB. Cytokines. 3. Cytokines in asthma. Thorax. 1993 Aug;48(8):845–853. [PMC free article] [PubMed]
  • Schleimer RP. Effects of glucocorticosteroids on inflammatory cells relevant to their therapeutic applications in asthma. Am Rev Respir Dis. 1990 Feb;141(2 Pt 2):S59–S69. [PubMed]
  • Bédard M, McClure CD, Schiller NL, Francoeur C, Cantin A, Denis M. Release of interleukin-8, interleukin-6, and colony-stimulating factors by upper airway epithelial cells: implications for cystic fibrosis. Am J Respir Cell Mol Biol. 1993 Oct;9(4):455–462. [PubMed]
  • Llewellyn-Jones CG, Hill SL, Stockley RA. Effect of fluticasone propionate on neutrophil chemotaxis, superoxide generation, and extracellular proteolytic activity in vitro. Thorax. 1994 Mar;49(3):207–212. [PMC free article] [PubMed]
  • Dechaux M, Broyer M, Lenoir G, Limal JM, Sachs C. Nyctohemeral rhythm of plasma renin activity and plasma aldosterone in children. Pediatr Res. 1982 May;16(5):354–356. [PubMed]
  • Pantin CF, Stead RJ, Hodson ME, Batten JC. Prednisolone in the treatment of airflow obstruction in adults with cystic fibrosis. Thorax. 1986 Jan;41(1):34–38. [PMC free article] [PubMed]
  • Rosenstein BJ, Eigen H. Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics. 1991 Feb;87(2):245–246. [PubMed]
  • Wheeler WB, Williams M, Matthews WJ, Jr, Colten HR. Progression of cystic fibrosis lung disease as a function of serum immunoglobulin G levels: a 5-year longitudinal study. J Pediatr. 1984 May;104(5):695–699. [PubMed]
  • Greally P, Hussain MJ, Vergani D, Price JF. Interleukin-1 alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Arch Dis Child. 1994 Jul;71(1):35–39. [PMC free article] [PubMed]
  • Dagli E, Warner JA, Besley CR, Warner JO. Raised serum soluble interleukin-2 receptor concentrations in cystic fibrosis patients with and without evidence of lung disease. Arch Dis Child. 1992 Apr;67(4):479–481. [PMC free article] [PubMed]
  • Greally P, Hussain MJ, Vergani D, Price JF. Serum interleukin-1 alpha and soluble interleukin-2 receptor concentrations in cystic fibrosis. Arch Dis Child. 1993 Jun;68(6):785–787. [PMC free article] [PubMed]
  • Majure M, Mroueh S, Spock A. Risk factors for the development of posterior subcapsular cataracts in patients with cystic fibrosis and allergic bronchopulmonary aspergillosis treated with corticosteroids. Pediatr Pulmonol. 1989;6(4):260–262. [PubMed]
  • Hodson ME. Diabetes mellitus and cystic fibrosis. Baillieres Clin Endocrinol Metab. 1992 Oct;6(4):797–805. [PubMed]
  • Dove AM, Szefler SJ, Hill MR, Jusko WJ, Larsen GL, Accurso FJ. Altered prednisolone pharmacokinetics in patients with cystic fibrosis. J Pediatr. 1992 May;120(5):789–794. [PubMed]
  • Russell G. Inhaled corticosteroid therapy in children: an assessment of the potential for side effects. Thorax. 1994 Dec;49(12):1185–1188. [PMC free article] [PubMed]
  • Schiøtz PO, Jørgensen M, Flensborg EW, Faerø O, Husby S, Høiby N, Jacobsen SV, Nielsen H, Svehag SE. Chronic Pseudomonas aeruginosa lung infection in cystic fibrosis. A longitudinal study of immune complex activity and inflammatory response in sputum sol-phase of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infections: influence of local steroid treatment. Acta Paediatr Scand. 1983 Mar;72(2):283–287. [PubMed]
  • van Haren EH, Lammers JW, Festen J, Heijerman HG, Groot CA, van Herwaarden CL. The effects of the inhaled corticosteroid budesonide on lung function and bronchial hyperresponsiveness in adult patients with cystic fibrosis. Respir Med. 1995 Mar;89(3):209–214. [PubMed]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press